Regimen Overview Overall Response Rate Survival Outcomes
Single agent Rituximab4
Low tumor burden, poor performance status, slowly progressive
66% (initial) 40% (re-treatment) mPFS: 21 months (initial) mPFS: 18 months (re-treatment)
Rituximab + Chemo†5
First relapse, or late relapse
RR 1.28 favoring R-chemo
HR for mortality: 0.63 2y OS: 90%
Obinutuzumab+Bendamustine6 Rituximab refractory 57% mPFS: 25.8 months
Anti-CD20 + lenalidomide7,9
Late or early relapse
65-77%
mPFS: 39 months mTTP: 24 months
Lenalidomide9 Late or early relapse 53% mTTP: 13.2 months
Idelalisib10 After two prior therapies 57% mPFS: 11 months
Tazemetostat11 EZH2 mutation in first relapse 69% mPFS: 11 months
Autologous HSCT12 Early treatment failure 78% 5y OS 73%
Axicabtagene ciloleucel2 After two prior therapies 95% 12 month DOR: 71.7%
Pembrolizumab13 After failed CAR-T 27% n/a
Lenalidomide +/-anti-CD2014
After failed CAR-T
63.6% (within 15 days of CAR-T infusion) 18.8% (15 days after CAR-T infusion)
n/a